Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ironwood Pharmaceuti (NQ: IRWD ) 6.520 +0.320 (+5.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 28, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Ironwood Pharmaceuti < Previous 1 2 3 Next > Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Late-Breaker Oral Presentation at Digestive Disease Week® Reinforces Potential of Once-Weekly Apraglutide for Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) May 21, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports First Quarter 2024 Results May 09, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference May 06, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 May 01, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call April 25, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) March 28, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) February 29, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference February 23, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance February 15, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call February 01, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation January 08, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance January 08, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio December 12, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management November 30, 2023 Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... Via Newsfile Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference November 21, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Third Quarter 2023 Results November 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call October 26, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting October 23, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week October 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old October 05, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance August 08, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call July 25, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares June 29, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio June 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old June 12, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases May 22, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Participate in The JMP Securities Life Sciences Conference May 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023 May 08, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.